Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-d-glucose with positron emission tomography in patients with small cell lung cancer

[1]  C. Rudin,et al.  Small Cell Lung Cancer , 2022 .

[2]  Y. Shim,et al.  Occult nodal metastasis in patients with non‐small cell lung cancer at clinical stage IA by PET/CT , 2010, Respirology.

[3]  Kyung Soo Lee,et al.  Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications , 2010, Annals of Surgical Oncology.

[4]  A. Scott,et al.  High Impact of 18F-FDG-PET on Management and Prognostic Stratification of Newly Diagnosed Small Cell Lung Cancer , 2010, Molecular Imaging and Biology.

[5]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[6]  R. Coleman,et al.  NCCN task force: clinical utility of PET in a variety of tumor types. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  Roland L Bassett,et al.  18F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma , 2009, Journal of Nuclear Medicine.

[8]  N. Holalkere,et al.  Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  Michael E Phelps,et al.  Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas , 2008, Journal of Nuclear Medicine.

[10]  Quynh-Thu Le,et al.  Metabolic tumor burden predicts for disease progression and death in lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[11]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[12]  P. Grigsby,et al.  FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. , 2006, International journal of radiation oncology, biology, physics.

[13]  D. Jackman,et al.  Small-cell lung cancer , 2005, The Lancet.

[14]  R. Hustinx,et al.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose , 1996, European Journal of Nuclear Medicine.

[15]  E. Stoelben,et al.  Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  D. Ball,et al.  Impact of Positron Emission Tomography on the Management of Patients With Small-Cell Lung Cancer: Preliminary Experience , 2004, American journal of clinical oncology.

[17]  J. Hengstler,et al.  Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? , 2002, Lung cancer.

[18]  T. Miller,et al.  Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[19]  A. Lammertsma,et al.  Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.

[20]  Larson,et al.  Tumor Burden Assessment with Positron Emission Tomography with , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[21]  Cnmt,et al.  Detection of Recurrent Brain Tumor. Comparison of MR Registered Camera-Based and Dedicated PET Images. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[22]  J. Wasserman,et al.  Effect of radiotherapy on blood lymphocyte population in mammary carcinoma. , 1976, International journal of radiation oncology, biology, physics.